Larimar Targets FDA Filing for Friedreich’s Ataxia Drug
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) plans to begin a rolling FDA biologics license application submission next month for its experimental Friedreich’s ataxia treatment nomlabofusp as the …
Larimar Targets FDA Filing for Friedreich’s Ataxia Drug Read More